CL
EW icon

Croft-Leominster’s Edwards Lifesciences EW Stock Holding History

Croft-Leominster’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-369,852
Closed -$4.57M – 196
2014
Q1 		$4.57M Sell
369,852
-54,336
-13% -$627K 0.73% 58
2013
Q4 		$4.65M Sell
424,188
-24,768
-6% -$279K 0.7% 57
2013
Q3 		$5.21M Sell
448,956
-37,326
-8% -$437K 0.85% 47
2013
Q2 		$5.45M Buy
+486,282
New +$5.76M 0.8% 47

Other funds holding EW

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Croft-Leominster's EW Position: Q2 2014 in Review

Croft-Leominster sold out of Edwards Lifesciences (EW) in Q2 2014, closing a stake of 369,852 shares — an estimated $4.57M sold.

Croft-Leominster first reported a position in EW in Q2 2013 and held it in 4 quarters. The position peaked at $5.45M in Q2 2013. 429 funds tracked by Wall St. Rank hold EW as of Q2 2014.

  • Croft-Leominster reported no remaining Edwards Lifesciences position as of Q2 2014 after selling out during the quarter.
  • Croft-Leominster sold 369,852 Edwards Lifesciences shares in Q2 2014, an estimated $4.57M.
  • Croft-Leominster first reported a position in Edwards Lifesciences in Q2 2013 and held it in 4 quarters.
  • Croft-Leominster's Edwards Lifesciences position peaked at $5.45M in Q2 2013.
  • 429 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2014.

Based on Croft-Leominster's 13F filing for Q2 2014, filed 14 Aug 2014.